The changes of QoL between groups showed that PD-1/PD-L1 inhibitors were more beneficial than chemotherapy; furthermore, there was a statistically significant favorable change among NSCLC treated with PD-1/PD-L1 inhibitors in the QLQ-C30 during the follow-up duration. The gene discussed is CD274; the disease is non-small cell lung carcinoma.